Alnylam successfully completed a multi-pronged financing deal with the investment firm, which it will use to fund the development of more RNAi drugs.
Alnylam Pharmaceuticals Inc. closed an impressive $2bn financing from the investment firm Blackstone, despite the volatile environment caused by COVID-19. The biopharma said it will use the investment to fund the development of more RNAi drugs and achieve long-term sustainability, announcing the multi-pronged agreement on 13 April.
"This new relationship with Blackstone provides Alnylam with very significant capital that we believe secures our bridge towards achieving a...
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
